Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC

NCT06829641 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Stage IIIB, NSCLC Stage IIIC

Interventions

PROCEDURE: Tislelizumab Combined with Chemotherapy,

Sponsor

West China Hospital